New StripAssay from Viennalab : NRAS
A new StripAssay, supplementing our range of cancer pharmacogenomic products (KRAS, BRAF, EGFR, FCGR), is being released: The NRAS StripAssay (Cat.# 5-610) detects 12 different mutations within the critical codons 12, 13 and 61 of the NRAS gene. It is capable of detecting mutations at a level of 1 percent in a background of wild-type NRAS.
The effectiveness of the anti-EGFR monoclonal antibodies cetuximab (Erbitux) and panitumumab (Vectibix) is very well established in KRAS non-mutated colorectal cancer (CRC) patients. Patients that harbour KRAS mutations, on the other hand, have been found to be resistant to those therapies. NRAS, another member of the ras gene family, is also mutated in CRC and various other tumors. Recently the PRIME Study showed that not only KRAS, but also NRAS mutations, will predict a lack of response to panitumumab. AMGEN, the manufacturer of Vectibix, meanwhile released a safety note recommending NRAS testing before starting panitumumab therapy.